SOURCE: Research and Markets

Research and Markets

February 17, 2016 07:31 ET

Orphan Drugs Market Expected to Grow at CAGR of 10.05% -- Key Vendors Are Bristol-Mayer Squibb, Celgene, F.Hoffmann La Roche, Novartis & Pfizer

DUBLIN, IRELAND--(Marketwired - February 17, 2016) - Research and Markets has announced the addition of the "Orphan Drugs Market 2015-2019" report to their offering.

The global orphan drugs market is expected to grow at a CAGR of 10.05% over the period 2015-2019.

The market is expected to witness certain emerging trends. Among these is an increased focus on biologics. Biologics are expected to be a preferred treatment option for the medical fraternity, patients, and the families of patients. This in turn will raise the number of treatment-seeking patients, which results in an increase in the overall consumption of medicines.

According to the report, another key driver is the shorter development timelines. The clinical trials for orphan indication enrol fewer patients in the studies, which leads to a shorter and faster development process.

Further, the report states that one of the challenges in conducting clinical trials in rare diseases is the smaller number of patients available for clinical studies. Enrolling enough patients in clinical studies to generate significant comparative data is therefore a major challenge.

Key questions answered in this report:

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the Key Market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Key vendors:

  • Bristol-Mayer Squibb
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer

Other prominent vendors:

  • AbbVie
  • Actelion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Baxter International
  • Biogen Idec
  • Celldex Therapeutics
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novo Nordisk
  • Onyx Pharmaceuticals
  • Sanofi
  • Shire
  • Synageva BioPharma
  • Takeda
  • Vertex Pharmaceuticals
  • XOMA

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview

PART 06: Pipeline snapshot

PART 07: Market landscape

PART 08: Market segmentation by product

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/qhkdqn/orphan_drugs.

Sector: Pharmaceuticals

Contact Information

  • Research and Markets
    Laura Wood,
    Senior Manager
    press@researchandmarkets.com

    Fax from USA: 646-607-1907
    Fax from rest of the world: +353-1-481-1716